Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Rifasutenizol with Midazolam and Clarithromycin in Healthy Participants
NCT06551623Phase 1Completed
- Sponsor
- TenNor Therapeutics
- Start
- Aug 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rifasutenizol in Helicobacter pylori infection (2 cohorts), sponsored by TenNor Therapeutics. Primary endpoints: Area under the plasma concentration versus time curve (AUC0-t) of Midazolam at Day 10, Area under the plasma concentration versus time curve from time 0 extrapolated to infinity (AUC0-inf) of Midazolam at Day 10 and 4 more. Started Aug 2024; status: completed.
02
Drugs
rifasutenizol
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06551623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551623.